10:47 AM EST - BriaCell Therapeutics Corp. : Announces that the independent Data Safety Monitoring Board (DSMB) has issued its seventh consecutive positive recommendation following review of clinical data from BriaCell’s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer. BriaCell Therapeutics Corp.
shares T.BCT are trading up $0.02 at $5.06.
